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Abstract
Tick bite fever has been a constant feature of the South African medical landscape. While it was recognised many years ago that 
there was a wide spectrum of clinical severity of infection, only recently has it been established that there are two aetiological agents, 
with different epidemiologies and clinical presentations. Rickettsia conorii infections resemble the classical Mediterranean spotted 
fever (fièvre boutonneuse), and patients are sometimes at risk of severe or even fatal complications. On the other hand, African tick 
bite fever is a separate entity caused by Rickettsia africae and tends to be a milder illness, with less prominent rash and little tendency 
to progress to complicated disease. Irrespective of the agent, the treatment of choice for tick bite fever in South Africa remains doxy-
cycline or tetracycline, and the role of macrolide and quinolone antibiotics is still unclear, or at least restricted. 
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Introduction
The rickettsiae comprise a diverse group of bacterial organisms 
responsible for various clinical entities globally. With a couple of 
exceptions, all are vector-borne. In South Africa the most common 
rickettsial disease is tick bite fever (TBF). Two typical clinical scenarios 
are presented for consideration.
Case 1
A 60-year-old farmer in North-West Province complains of fever 
and severe headache a few days after removing ticks from his 
dogs. Four days later he becomes confused and is admitted 
to hospital. He is found to be hypotensive, with a generalised 
maculopapular rash that rapidly becomes confluent and 
haemorrhagic in places. The leukocyte count is 2 x 109/L with an 
absolute neutrophilia; there is profound thrombocytopenia, hepatic 
transaminases are four times normal and there is evidence of renal 
failure. The Weil-Felix test is negative, and smears for malaria are 
repeatedly negative. He is started on ceftriaxone for a possible 
bacterial septicaemia. Blood cultures are negative. Tests for 
Crimean-Congo fever are negative. No ticks or tick bites are found. 
Two days after admission the patient dies of multi-organ failure. 
What diseases would you include in your differential diagnosis? 
Case 2 
A three-year-old child complains of a headache seven days after 
visiting a farm in Mpumalanga Province. She is febrile (39ºC), with 
a painful cervical lymph node, and an eschar is found on the scalp. 
Three days later she develops a sparse maculopapular rash on the 
trunk and palms and soles. How would you manage the patient?
Discussion
The earliest description of the disease resembling boutonneuse or 
Mediterranean spotted fever in southern Africa dates back to 1911. 
In 1931 Troup and Pijper published their classic description of South 
African TBF, which distinguished between mild and severe forms of the 
disease.1  Unfortunately, laboratory correlates of this distinction were 
subsequently lost, and the result was that Rickettsia conorii var pijperi 
became accepted as the sole agent of South African TBF. In 1992, 
however, a different rickettsial species responsible for some cases of 
TBF was identified by molecular techniques, and was named Rickettsia 
africae.2 There are therefore at least two TBF diseases of southern 
Africa: boutonneuse fever-like TBF (caused by R. conorii) and African 
TBF (caused by R. africae).  
The former is usually transmitted by dog ticks in a peri-urban or peri-
domestic setting, with dogs, rodents and ticks themselves forming the 
reservoir. In contrast, African TBF is typically transmitted by specific 
cattle and game ticks (Amblyomma hebraeum) in rural settings of 
southern Africa (see Figure 1). Surveys have shown up to 70% 
seroprevalence in sub-Saharan  areas where Amblomma ticks and 
cattle farming coincide.3 Notwithstanding this, there are very few 
clinical case reports of TBF in indigenous populations,4 presumably 
because of mild or inapparent disease and consequent lack of clinical 
recognition. In Zimbabwe annual case incidence rates of African 
TBFhave been estimated as 60 to 80 per 10 000 patients.5 TBF is 
commonly recognised in non-African patients in South Africa but the 
incidence is not known. The incidence rates of infection have been 
estimated to be in the region of 4–5% in visitors from Europe, which 
are higher than those for other febrile illnesses such as malaria and 
typhoid fever. There is a large population at risk, e.g. game reserve 
visitors, hunters, soldiers and farmers.6  
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Figure 1: Ambyomma hebreum, adult male (Photo: Dr P Jupp, A Kemp)
Clinical features
As indicated above, TBF is common in South Africa, although 
recognised cases are probably far outnumbered by subclinical ones. 
Larval- and nymph-stage ticks typically transmit the diseases; larvae 
(‘pepper ticks’) are often unnoticed on the body because they are so 
small. R conorii infections (boutonneuse fever-type TBF) begin after an 
incubation period of five to seven days, with a consistent prodrome of 
malaise, fever, headache, nightmares and myalgia. The eschar is the 
primary lesion and marks the site of attachment of the infected tick; it 
consists of a central necrotic area surrounded by inflamed skin (see 
Figure 2). The eschar is not always apparent; it may be under scalp 
hair, behind the ear, in the anogenital area or on other cryptic body 
sites.  Dog owners who crush engorged ticks are at risk for acquiring 
infection via conjunctival splashes (see Case 1). About three days 
after the onset of symptoms, the rash appears. It is usually a coarse 
maculopapular eruption involving the palms and soles (see Figure 3).  
Figure 2: Tick bite fever eschar (Photo: Dr J Hyslop)
Clinical presentation varies from very mild to severe and even fatal 
disease; the latter occurs particularly in elderly or debilitated people 
but is not limited to this group.7  Complications include encephalitis, 
confusion or coma, pneumonia, pulmonary embolism following deep 
vein thrombosis, consumptive coagulopathy, bleeding, gangrene, 
hepatorenal failure and myocarditis. Rarely, but particularly when 
treatment is delayed, TBF cases can present with multi-organ 
involvement and mimic meningococcal septicaemia, other fulminant 
Gram-negative septicaemia or even a viral haemorrhagic fever, most 
commonly being confused with Crimean-Congo haemorrhagic fever 
(CCHF) (as in Case 1). The incubation period from tick bite to clinical 
disease differs in the two diseases; one to three days following tick-
transmitted CCHF and usually five to seven days in TBF. African TBF 
(R africae) tends to be a milder disease in general, and life-threatening 
complications have not been described,3 although significant acute 
neuropsychiatric features8 as well as prolonged sub-acute neuropathy9 
have been described. The African TBF prodrome is similar to that of 
R conorii infection; characteristic, but not consistent, distinguishing 
features are multiple eschars, tender regional lymphadenopathy, 
rashless illness or only scattered and/or vesicular rash elements. 
Aphthous stomatitis was noted in 11% of a series of 38 patients.6
Diagnostic issues
The classical clinical triad of fever, eschar and rash occurs in 50–75% 
of cases of TBF, but there are less typical presentations. The eschar 
may resemble an infected insect bite or other skin trauma or an early 
anthrax lesion. The rash may suggest rubella, measles, secondary 
syphilis, disseminated gonococcal disease, enterovirus or arbovirus 
infections, leptospirosis, typhoid, immune complex vasculitis or drug 
reactions (see Figure 4). Meningococcal rashes can look similar, 
but the onset and progression of illness is much faster than in TBF. 
During the non-specific prodromal period, malaria is an important 
differential diagnosis in travellers. Serological tests are often negative 
early in the disease and repeat testing is required; treatment should 
not be delayed solely because of negative serology.  Specific micro-
immunofluorescence is the serological method of choice; the two 
species share antigens and are not routinely distinguishable, but this 
does not affect treatment. The Weil-Felix agglutination test is now 
regarded as obsolete as it is neither sensitive nor specific. In most 
patients the white blood cell count remains within the normal range 
with neutrophilia being typical. In complicated disease neutropenia and 
thrombocytopenia may be noted.
Figure 3:  Typical coarse maculopapular rash of tick bite fever (Photo: Dr B Miller)
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Figure 4: Purpuric rash in severe tick bite fever (Photo: Dr B Miller)
Treatment
Large-scale clinical trials of treatment for TBF have not been done. 
Some infections may be mild, but TBF can be very severe and 
therapeutic delay should be avoided. Tetracycline-group antibiotics, 
particularly doxycycline, are the treatment of choice. For adults, 
doxycycline 100 mg bd for five to seven days is recommended 
although shorter courses may be adequate.10 Doxycycline is 
highly effective and a clinical response with symptom relief and 
defervescence can be expected within 48 hours. Failure of response 
within this period should suggest the possibility of another diagnosis. 
Chloramphenicol and the 4-fluorinated quinolones show in-vitro activity, 
but clinical data on efficacy is limited.11 However, a 4-fluorinated 
quinolone such as ciprofloxacin, or chloramphenicol, may be the 
only available option in critically ill patients unable to tolerate oral 
medication, as parenteral tetracycline is unavailable in South Africa. 
Erythromycin has poor efficacy and there is insufficient clinical data 
to recommend the new macrolides such as clarithromycin and 
azithromycin,11,12 although they may have a place in supplementing 
initial doxycycline treatment. As TBF can be life-threatening in patients 
of any age group, treatment with the most effective agent, doxycycline, 
is the recommended therapy for all patients. Therefore, doxycycline 
should be strongly considered at least for initial therapy even in 
children under eight years of age and pregnant women (see Case 2). 
An initial treatment of two days of doxycycline should be given followed 
by three to five days of a macrolide to complete the therapeutic course. 
Limited data supports the use of steroids in patients with fulminant 
TBF, or disease complicated by acute respiratory distress. Most of the 
experience of steroids in rickettsial disease can be extrapolated from 
their use in patients with complicated Rocky Mountain spotted fever.12 
Conclusion
The diagnosis of TBF is usually readily made if the classic triad of 
fever, rash and eschar is apparent. Less typical forms of TBF present 
with a wide range of clinical features and severity. The treatment of 
coice is doxycycline or tetracycline.  
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